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Genes involved in the coenzyme Q10 biosynthetic pathway (COQ2, COQ6, PDSS1, PDSS2 and 
ADCK4) are mutated in about 1% of Steroid Resistant Nephrotic Syndrome (SRNS) cases and are 
often associated with neurological symptoms [1; 2]. Here we describe novel phenotypes associated 
with pathogenic mutations in two genes of the CoQ10 pathway, COQ2 and COQ6, in three patients 
with SRNS. One novel homozygous COQ2 variant, p.Gly390Ala (p.Gly340Ala, according to 
KU877220 GenBank sequence [2]) was identified by NGS (Supplementary Information) in two 
cousins (Patients P1 and P2; Figure 1A; Tables S1 and S2) with SRNS associated with focal 
segmental glomerulosclerosis (FSGS) lesions and podocyte foot process effacement on renal biopsy 
(Figure 1B, panels 1-4; Table S1). The pathogenicity of this variant is supported by its absence in 
public SNP database; the segregation with the disease (Figure S1, panel 1); in silico predictions 
(Figure 1C, Table S2); the reduced rate of respiratory growth and CoQ levels of yeast expressing 
this allele (Figure 1D); the presence of numerous dysmorphic mitochondria on renal biopsy (Figure 
1B, panels 5 and 6). Remarkably, both patients harbouring COQ2 change developed SRNS in 
adolescence with rapid progression to end stage renal disease (ESRD) and had only mild 
neurological symptoms (Table S1). Of note, both cousins received a successful kidney transplant 
without recurrence of proteinuria and started CoQ10 treatment immediately after the genetic 
diagnosis. They are currently asymptomatic without any neurological symptoms after a 2-year 
follow-up. Other authors reported patients with inherited COQ2 changes presented with isolated 
renal symptoms [2], however, to date, the reported age of onset of SRNS in patients carrying COQ2 
variants was before the age of 2.5 years [2]. To our knowledge, this is the first report describing 
COQ2 variants in patients with adolescent-onset SRNS and with a clinical spectrum resembling 
another CoQ10-glomerulopathy caused by mutations in ADCK4 [3]. This finding recapitulates what 
has been observed in the Pdss2 (kd/kd) mice [2] and can be explained by the relatively mild effect 
of the p.Gly390Ala (p.Gly340Ala) allele, as documented by yeast studies (Figure 1D).  
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Mutational screening of patient P3 (Figure 1E; Table S1) revealed a novel homozygous missense 
change in COQ6 gene: p.Pro261Leu (Figure 1F; Table S2). The functional effect of this variant is 
supported by its low MAF in the European population (1:16683, Table S2); the segregation with the 
disease (Figure S1, panel 2); in silico predictions (Figure 1G; Table S2) and the inability of COQ6 
p.Pro261Leu allele to rescue the growth defect of the deleted yeast (Figure 1H). Few patients with 
COQ6 changes (12) have been reported so far, they showed SRNS with onset at a median age of 1.2 
years and sensorineural deafness (7/12) but some had also encephalopathic features [4]. Our patient 
developed SRNS at 8 months with progressive deterioration of renal function and ESRD at 20 
months. Of note, he did not present deafness or encephalopathic features. He is now on peritoneal 
dialysis treatment, however CoQ10 treatment was started to prevent neurological symptoms. 
Interestingly, there was no history of schwannomatosis in the patient’s family, and unless further 
evidence supporting the link between heterozygous COQ6 mutations and schwannomatosis 
becomes available, we do not recommend mutational screening of COQ6 gene for Schwannomas 
carriers [5]. The most frequent glomerular lesion associated with COQ6 changes is FSGS [4]. 
Remarkably, the analysis of renal biopsy of our patient revealed membranoproliferative 
glomerulonephritis (MPGN) and C3 deposits (Figure 1F) usually associated with variants and risk 
haplotypes of complement-pathway genes, whose analysis did not reveal any variants with 
MAF<0.01 (data not shown). In summary, this study shows that we should analyze COQ2 and 
COQ6 genes also in patients with adolescent-onset of SRNS and without neurological symptoms, to 
avoid unnecessary immunosuppressive therapies and provide timely and effective treatment with 
CoQ10.  
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performed according to the guidelines of the Declaration of Helsinki and the local Ethics 
Committees of University Hospitals of Foggia and Bari (Italy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
REFERENCES 
1. Sadowski CE, Lovric S, Ashraf S, et al. SRNS Study Group, Hildebrandt F. A single-gene 
cause in 29,5% of cases of Steroid-Resistant Nephrotic Syndrome. J Am Soc Nephrol 2015: 
26(6): 1279-1289. 
2. Desbats MA, Morbidoni V, Silic-Benussi M, et al. The COQ2 genotype predicts the severity 
of Coenzyme Q10 deficiency. Hum Mol Genet 2016: ddw257 [Epub ahead of print]. 
3. Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, et al. ADCK4-Associated Glomerulopathy 
Causes Adolescence-Onset FSGS. J Am Soc Nephrol 2016: 27(1): 63-68. 
4. Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce 
nephrotic syndrome with sensorineural deafness. J Clin Invest 2011: 121(5): 2013-2024. 
5. Trevisson E, Clementi M, Salviati L. Is there a link between COQ6 and schwannomatosis? 
Genet Med 2015: 17(4): 312-313.   
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
FIGURE L
Figure 1. 
images (C
Pro261. (D
pCM189 p
human CO
in plates co
strains wer
Complex 
mitochond
EGEND 
(A; E): Fa
; G): Evol
; H): W30
lasmid exp
Q2 p.Gly3
ntaining gl
e grown in
II+III (C.I
ria. ND=no
mily 1; Fa
utionary co
3∆COQ2 
ressing eit
90Ala (Gly
ycerol as so
 liquid me
I+III) and
t detectable
mily 2 (B;
nservation 
and BY474
her wild ty
340Ala) an
le carbon s
dium conta
 Citrate S
.  
 F): Light
of COQ2
1∆COQ6 y
pe human
d COQ6 p
ource (YPG
ining 2% 
ynthase (
 microscop
Gly390 (K
easts were
 COQ2 an
.Pro261Leu
ly) for 3 a
galactose fo
CS) activi
y, immuno
U877220: 
 transform
d COQ6, t
 alleles, re
nd 5 days, r
r 3 or 4 d
ties were 
fluorescenc
p.Gly340) 
ed with the
he empty 
spectively, 
espectively
ays, respec
assayed o
e and EM
and COQ6
 low copy
vectors, or
and grown
. The same
tively, and
n purified
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
